SEC Filing Summary: GSK Plc (13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by GSK Plc, an institutional investment manager based in London. The report covers the calendar quarter ended June 30, 2026, and was signed on August 13, 2026, by Victoria Whyte, the Authorized Signatory.
Key Financial Metrics
As a Form 13F-HR, this document discloses equity holdings rather than the company's own operating financials. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity for GSK Plc's operations are not present in this filing.
- Total Value of Reported Holdings: $602,220,442
- Number of Holdings Reported: 13
- Other Included Managers: None
Material Changes
The filing text does not provide comparative data for the prior period; therefore, material changes in holdings value or composition cannot be determined from this document alone.
Guidance, Outlook, and Risks
This form is a regulatory disclosure of investment positions and does not contain management commentary, future guidance, risk factors, or contingencies regarding GSK Plc's business operations.
Investor Verification Checklist
- Verify the specific 13 equity securities held by GSK Plc in the full Schedule 13F (not included in this summary text).
- Confirm the total market value of $602,220,442 against the sum of individual holdings in the full schedule.
- Note that this filing reflects GSK Plc's role as an investment manager, not its own corporate financial performance.